| Literature DB >> 35982217 |
Hirohiko Niioka1, Teruyoshi Kume2, Takashi Kubo3, Tsunenari Soeda4, Makoto Watanabe4, Ryotaro Yamada2, Yasushi Sakata5, Yoshihiro Miyamoto6, Bowen Wang1, Hajime Nagahara7, Jun Miyake7, Takashi Akasaka3, Yoshihiko Saito4, Shiro Uemura8.
Abstract
This study sought to develop a deep learning-based diagnostic algorithm for plaque vulnerability by analyzing intravascular optical coherence tomography (OCT) images and to investigate the relation between AI-plaque vulnerability and clinical outcomes in patients with coronary artery disease (CAD). A total of 1791 study patients who underwent OCT examinations were recruited from a multicenter clinical database, and the OCT images were first labeled as either normal, a stable plaque, or a vulnerable plaque by expert cardiologists. A DenseNet-121-based deep learning algorithm for plaque characterization was developed by training with 44,947 prelabeled OCT images, and demonstrated excellent differentiation among normal, stable plaques, and vulnerable plaques. Patients who were diagnosed with vulnerable plaques by the algorithm had a significantly higher rate of both events from the OCT-observed segments and clinical events than the patients with normal and stable plaque (log-rank p < 0.001). On the multivariate logistic regression analyses, the OCT diagnosis of a vulnerable plaque by the algorithm was independently associated with both types of events (p = 0.047 and p < 0.001, respectively). The AI analysis of intracoronary OCT imaging can assist cardiologists in diagnosing plaque vulnerability and identifying CAD patients with a high probability of occurrence of future clinical events.Entities:
Mesh:
Year: 2022 PMID: 35982217 PMCID: PMC9388661 DOI: 10.1038/s41598-022-18473-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Study flow chart. OCT optical coherence tomography, AI artificial intelligence.
Figure 2Clinical OCT images and their corresponding raw images. OCT of a normal (a), a stable plaque (b), and a vulnerable plaque (c) diagnosed by OCT expert cardiologists. The clinical OCT images in (a–c) were generated from corresponding raw data (d–f) by a polar coordinate transformation.
Figure 3Grad-CAM analysis and t-SNE visualization of the last hidden layer for the three types of OCT imaging. Normal (a), stable (b), and vulnerable (c) OCT images. (d–f) Images of (a–c) overlaid with the attention map output by Grad-CAM. Expert cardiologists usually differentiate vulnerable plaque from stable plaque based on the thickness of the fibrous cap overlying the lipid component in OCT image. It is interesting to note that for stable and vulnerable plaques, the attention is on a part of the fibrous cap overlying the lipid component, whereas for normal plaques, the attention is given to the whole vessel wall in the attention map output by Grad-CAM. The high-dimensional features obtained by DenseNet-121 are dimensionally compressed by t-SNE and are represented as two-dimensional data (g). A total of 1,173 images of the test dataset that was obtained from 102 patients are displayed. Normal (N), stable plaque (S), and vulnerable plaque (V) images are represented as green, yellow, and red dots, respectively. The normal, stable plaque, and vulnerable plaque clusters are clearly observed. Some stable plaque data are included in the normal cluster, which is consistent with the results of the confusion matrix (Fig. 4a).
Figure 4Diagnostic accuracy of the developed AI algorithm. Diagnostic accuracies of plaque vulnerability between the developed AI algorithm (a) and the general cardiologists (b) compared to the reference of the OCT-expert diagnosis. Receiver operating characteristic (ROC) curves for the AI algorithm for the differentiation of normal vessels (c), stable plaques (d), and vulnerable plaques (e). The dot plots represent the diagnostic accuracy of each general cardiologist.
Clinical characteristics of the patients in dataset 3 according to the classification by the AI algorithm.
| Overall (n = 1450) | Vulnerable (n = 550) | Stable (n = 465) | Normal (n = 435) | p value | |
|---|---|---|---|---|---|
| Age (years) | 68.0 ± 11.3 | 69.0 ± 10.8* | 67.8 ± 10.8 | 66.9 ± 12.3 | 0.022 |
| Male | 1081 | 412 | 365 | 304 | 0.012 |
| Body mass index (kg/m2) | 23.9 ± 3.7 | 23.7 ± 3.7 | 24.1 ± 3.6 | 24.0 ± 3.9 | 0.260 |
| Hypertension | 1071 | 422 | 361 | 288 | < 0.001 |
| Diabetes mellitus | 544 | 223 | 184 | 137 | 0.006 |
| Dyslipidemia | 1029 | 377 | 351 | 301 | 0.042 |
| Current smoker | 349 | 160 | 95 | 94 | 0.014 |
| Prior myocardial infarction | 428 | 127 | 168 | 133 | < 0.001 |
| Prior PCI | 671 | 173 | 286 | 212 | < 0.001 |
| < 0.001 | |||||
| Acute coronary syndrome | 495 | 353 | 87 | 55 | |
| Chronic coronary artery disease | 644 | 152 | 281 | 211 | |
| Others | 311 | 45 | 97 | 169 | |
| Serum creatinine (mg/dL) | 1.17 ± 1.55 | 1.28 ± 1.73 | 1.15 ± 1.40 | 1.08 ± 1.45 | 0.121 |
| eGFR (mL/min/1.73 m2) | 66.0 ± 23.5 | 65.1 ± 25.6 | 64.4 ± 21.4† | 68.6 ± 22.4 | 0.025 |
| HbA1c (%) | 6.35 ± 1.11 | 6.45 ± 1.28* | 6.34 ± 0.96 | 6.26 ± 1.07 | 0.060 |
| LDL-Cho (mg/dL) | 96.5 ± 31.1 | 104.3 ± 34.2*‡ | 88.4 ± 28.8† | 96.4 ± 30.0 | < 0.001 |
| HDL-Cho (mg/dL) | 48.1 ± 13.0 | 46.9 ± 12.1* | 47.9 ± 12.6 | 49.5 ± 14.4 | 0.029 |
| Triglycerides (mg/dL) | 140 ± 87 | 138 ± 91 | 146 ± 90 | 135 ± 78 | 0.233 |
| Uric acid (mg/dL) | 5.66 ± 1.40 | 5.65 ± 1.41 | 5.76 ± 1.38 | 5.56 ± 1.39 | 0.136 |
| C-reactive protein (mg/dL) | 0.51 ± 1.58 | 0.54 ± 1.34 | 0.52 ± 1.72 | 0.46 ± 1.71 | 0.749 |
| BNP (pg/mL) | 146 ± 348 | 162 ± 280 | 114 ± 188 | 164 ± 506 | 0.131 |
| Antiplatelet therapy | 1183 | 430 | 388 | 365 | < 0.001 |
| Statins | 820 | 245 | 314 | 261 | < 0.001 |
| Beta-blockers | 487 | 146 | 198 | 143 | < 0.001 |
| ACEI/ARB | 742 | 265 | 266 | 211 | < 0.007 |
The values are presented as the means ± SD.
*p < 0.05 vulnerable vs. normal.
†p < 0.05 stable vs. normal.
‡p < 0.05 vulnerable vs. stable.
PCI percutaneous coronary intervention, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, LDL-Cho low-density lipoprotein cholesterol, HDL-Cho high-density lipoprotein-cholesterol, BNP brain natriuretic peptide, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker.
Figure 5Clinical outcomes in patients with CAD diagnosed by the AI algorithm. Kaplan–Meier curves of the event-free survival from the OCT-observed segments (a) and the composite of the clinical events (b) according to classification by the AI algorithm. Patients with OCT-diagnosed vulnerable plaques showed higher cumulative rates for both endpoints than the patients with OCT-diagnosed normal and stable plaques.
Events from the OCT-observed segments and the composite of clinical events.
| Events from the OCT-observed segments (n = 31) | Composite of the clinical events (n = 187) | |||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | p value | Odds ratio 95% CI p value | 95% CI | p value | |
| Age | 0.983 | 0.940–1.028 | 0.450 | 1.013 | 0.992–1.034 | 0.225 |
| Male | 3.057 | 0.651–14.347 | 0.157 | 1.353 | 0.802–2.282 | 0.257 |
| Hypertension | 0.915 | 0.332–2.523 | 0.864 | 0.923 | 0.558–1.524 | 0.751 |
| Diabetes mellitus | 1.350 | 0.563–3.238 | 0.502 | 1.221 | 0.810–1.842 | 0.340 |
| Dyslipidemia | 1.475 | 0.416–5.226 | 0.547 | 1.006 | 0.582–1.740 | 0.982 |
| Current smoker | 0.729 | 0.235–2.268 | 0.586 | 0.798 | 0.464–1.373 | 0.416 |
| Prior myocardial infarction | 1.053 | 0.308–3.600 | 0.934 | 0.750 | 0.436–1.292 | 0.301 |
| Prior PCI | 1.163 | 0.314–4.312 | 0.821 | 1.337 | 0.756–2.361 | 0.318 |
| Index clinical presentation: acute coronary syndrome | 0.637 | 0.203–1.996 | 0.439 | 1.228 | 0.750–2.012 | 0.414 |
| eGFR | 0.983 | 0.966–1.001 | 0.062 | 0.991 | 0.982–1.000 | 0.047 |
| LDL-Cho | 1.008 | 0.994–1.023 | 0.253 | 1.003 | 0.996–1.010 | 0.442 |
| HDL-Cho | 0.984 | 0.944–1.026 | 0.444 | 0.989 | 0.972–1.006 | 0.198 |
| Antiplatelet therapy | 0.727 | 0.198–0.673 | 0.631 | 0.896 | 0.477–1.683 | 0.733 |
| Statins | 0.706 | 0.217–2.299 | 0.563 | 0.892 | 0.512–1.554 | 0.688 |
| Beta-blockers | 2.087 | 0.718–6.063 | 0.177 | 1.023 | 0.638–1.650 | 0.916 |
| ACEI/ARB | 0.551 | 0.201–1.509 | 0.245 | 0.874 | 0.552–1.384 | 0.567 |
| Plaque characteristics: vulnerable plaque | 13.526 | 3.730–49.051 | < 0.001 | 2.295 | 1.478–3.562 | < 0.001 |
CI confidence interval, PCI percutaneous coronary intervention, eGFR estimated glomerular filtration rate, LDL-Cho low-density lipoprotein cholesterol, HDL-Cho high-density lipoprotein-cholesterol, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker.